TIDMPYC
RNS Number : 2969E
Physiomics PLC
29 June 2023
Unless otherwise defined herein, the capitalised defined terms
used in this announcement have the same meaning as those used in
the Company's announcements released on 27 June 2023 unless
otherwise defined herein.
29 June 2023
Physiomics plc
("PYC" or the "Company")
Completion of Fundraise to raise gross proceeds of GBP
380,477
Physiomics plc (AIM:PYC) is pleased to announce, further to its
announcements of 27 June 2023, the completion of the Subscription
and the WRAP Retail Offer, as well as the placing of an additional
2,000,000 Ordinary Shares on the same terms as the Placing
(together, the "Fundraise"). The Fundraise, which is conditional on
Admission, raises gross proceeds of, in aggregate, GBP380,477
through the issue of a total of 38,047,700 new Ordinary Shares (the
"Fundraise Shares").
Enlarged Placing
Further to the Company's announcement of 27 June 2023, the
Company is pleased to confirm that it has placed an additional
2,000,000 new Ordinary Shares on the same terms as the Placing,
through Hybridan LLP, taking the total placing to 34,500,000 new
Ordinary Shares raising gross proceeds of, in aggregate,
GBP345,000.
WRAP Retail Offer
The WRAP Retail Offer, which closed at 16:30 BST yesterday, has
raised gross proceeds of GBP 25,477 through the issue of 2,547,700
new Ordinary Shares to existing retail shareholders in the United
Kingdom.
Director Subscriptions
Further to the Company's announcement of 27 June 2023, the
Company can confirm that Dr James ('Jim') Millen (Executive
Chairman and CEO) and Dr Christophe Chassagnole (COO) have each
subscribed for GBP5,000 of new Ordinary Shares at the Placing price
pursuant to a direct subscription with the Company and accordingly
will each be issued 500,000 new Ordinary Shares. On Admission, Dr
Millen and Dr Chassagnole will be interested in, in aggregate,
1,884,393 and 1,102,723 Ordinary Shares respectively, representing
1.39% and 0.81% of the Company's then enlarged issued share
capital.
Use of Proceeds
In order to further develop its business and accelerate growth,
the Company targeted a raise of around GBP300,000 with the
intention of using the net proceeds of the Fundraise towards
activities including:
-- Further expansion and diversification of its client base;
-- Expansion of its consulting business into the adjacent area
of pharmaceutical biostatistics services; and
-- Exploration of opportunities around its personalised oncology software offering.
Admission and Total Voting Rights
Application has been made for the 38,047,700 Fundraise Shares to
be admitted to trading on AIM, which is expected to take effect and
dealings to commence at 8.00 a.m. on or around 3 July 2023
("Admission").
Following Admission, the Company will have 135,472,478 Ordinary
Shares in issue. Since the Company currently holds no shares in
treasury, the total number of voting rights in the Company will
therefore be 135,472,478 . These figures may therefore be used by
Shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the share capital of the Company
under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO +44 (0)1865 784 980
Hybridan LLP (Broker) +44 (0) 203 764 2341
Claire Louise Noyce
Strand Hanson Ltd (NOMAD) +44 (0)20 7409 3494
James Dance
James Bellman
Winterflood Retail Access Platform WRAP@winterflood.com
Alex Skrine, Head of Electronic Trading +44 (0) 20 3100 0009
Haris Khawaja, Corporate Finance +44 (0) 20 3100 0189
The Company's LEI is 213800A71DSZ6ABMTQ91
PDMR Notification Forms
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Jim Millen
-------------------------------- ---------------------------------------
2. Reason for the Notification
-------------------------------------------------------------------------
a) Position/status Executive Chairman and CEO
-------------------------------- ---------------------------------------
b) Initial notification/amendment Initial notification
-------------------------------- ---------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Physiomics plc
-------------------------------- ---------------------------------------
b) LEI 213800A71DSZ6ABMTQ91
-------------------------------- ---------------------------------------
4. Details of the transaction(s):section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv)each place where transactions have
been conducted
-------------------------------------------------------------------------
a) Description of the Financial Physiomics plc new Ordinary Shares
instrument, type of instrument
-------------------------------- ---------------------------------------
Identification code ISIN: GB00BDR6W943
-------------------------------- ---------------------------------------
b) Nature of the Transaction A subscription for new ordinary shares
in the Company
-------------------------------- ---------------------------------------
c) Price(s) and volume(s) Dr Jim Millen Price(s) Volume(s)
GBP0.01 500,000
----------
-------------------------------- ---------------------------------------
d) Aggregated information
* Aggregated volume 500,000
GBP0.01
* Price
-------------------------------- ---------------------------------------
e) Date of the transaction 28 June 2023
-------------------------------- ---------------------------------------
f) Place of the transaction Off market transaction
-------------------------------- ---------------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Christophe Chassagnole
-------------------------------- ------------------------------------------------
2. Reason for the Notification
----------------------------------------------------------------------------------
a) Position/status Executive Director, COO
-------------------------------- ------------------------------------------------
b) Initial notification/amendment Initial notification
-------------------------------- ------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------
a) Name Physiomics plc
-------------------------------- ------------------------------------------------
b) LEI 213800A71DSZ6ABMTQ91
-------------------------------- ------------------------------------------------
4. Details of the transaction(s):section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv)each place where transactions have
been conducted
----------------------------------------------------------------------------------
a) Description of the Financial Physiomics plc new Ordinary Shares
instrument, type of instrument
-------------------------------- ------------------------------------------------
Identification code ISIN: GB00BDR6W943
-------------------------------- ------------------------------------------------
b) Nature of the Transaction A subscription for new ordinary shares
in the Company
-------------------------------- ------------------------------------------------
c) Price(s) and volume(s) Dr Christophe Chassagnole Price(s) Volume(s)
GBP0.01 500,000
----------
-------------------------------- ------------------------------------------------
d) Aggregated information
* Aggregated volume 500,000
GBP0.01
* Price
-------------------------------- ------------------------------------------------
e) Date of the transaction 28 June 2023
-------------------------------- ------------------------------------------------
f) Place of the transaction Off market transaction
-------------------------------- ------------------------------------------------
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 100 projects, involving over 50 targets and
75 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014 as it forms part of
United Kingdom domestic law by virtue of the European Union
(Withdrawal) Act 2018, as amended by virtue of the Market Abuse
(Amendment) (EU Exit) Regulations 2019.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFLDRSITFIV
(END) Dow Jones Newswires
June 29, 2023 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
